Ancora Heart

Executive Summary

Ancora Heart is a private medical device company developing the AccuCinch® Ventricular Restoration System, a percutaneous implant designed to treat symptomatic heart failure with reduced ejection fraction (HFrEF). The device addresses a significant unmet need by restoring the geometry and function of the enlarged left ventricle in patients who remain symptomatic despite guideline-directed medical therapy. With over a decade of development, the company has generated encouraging early clinical data suggesting improvements in functional status and cardiac structure. As it approaches potential commercialization, Ancora Heart represents a promising investment thesis in the structural heart device space, targeting a large and growing patient population. The company's leadership in transcatheter ventricular restoration positions it to capture market share in the heart failure treatment paradigm, pending regulatory and clinical milestones.

Upcoming Catalysts (preview)

• Q3 2026Pivotal Trial Results (CORCINCH-HF) Readout65% success
• TBDFDA Approval Decision for AccuCinch System50% success
• TBDStrategic Partnership or Licensing Agreement40% success